Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

CONCLUSION: Pembrolizumab monotherapy has antitumor activity in heavily pretreated patients with mBC characterized by HTMB. Our findings support the recent US Food and Drug Administration approval of pembrolizumab for treatment of patients with unresectable or metastatic solid tumors with HTMB without alternative treatment options.PMID:33844595 | DOI:10.1200/JCO.20.02923

Source: Clinical Breast Cancer - April 12, 2021 Category: Cancer & Oncology Authors: Ajjai S Alva Pam K Mangat Elizabeth Garrett-Mayer Susan Halabi Damien Hansra Carmen J Calfa Maged F Khalil Eugene R Ahn Timothy L Cannon Pamela Crilley Julie G Fisher Derrick S Haslem Sagun Shrestha Kaitlyn R Antonelli Nicole L Butler Sasha L Warren Andre Source Type: research